Private equity firm Bridgepoint has sold UK drug development services company Quotient Clinical to specialist healthcare investor GHO Capital for a deal value understood to be around £165 million (€233 million; $247 million). Bridgepoint has held the for less than two years, and the exit is believed to represent an internal rate of return of 178 percent and a profit of 6.4 times the amount invested.
Read the full article by visiting Private Healthcare Investor.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: